Genital Diseases, Female  >>  bortezomib  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bortezomib / Generic mfg.
NCT00059618: PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Completed
1
21
US
PS-341 (Bortezomib), Velcade, LDP-341, MLN341, Carboplatin, Paraplatin
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
04/07
04/07
NCT00620295: Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Completed
1
17
US
bortezomib, Velcade, gemcitabine hydrochloride, Gemzar
Masonic Cancer Center, University of Minnesota
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
02/09
10/09
NCT00329589: A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Completed
1
54
US
Velcade (bortezomib)
Sidney Kimmel Cancer Center at Thomas Jefferson University, Millennium Pharmaceuticals, Inc.
Brain Cancer, Head and Neck Cancer, Cervix Cancer, Central Nervous System Neoplasms
06/10
06/10
NCT00028912: Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Completed
1
US
bortezomib, carboplatin
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
 
 

Download Options